CN107422116A - A kind of confirmation of the types of HIV 1/2 and the two-in-one reagent of primary dcreening operation based on percolation and preparation method thereof - Google Patents
A kind of confirmation of the types of HIV 1/2 and the two-in-one reagent of primary dcreening operation based on percolation and preparation method thereof Download PDFInfo
- Publication number
- CN107422116A CN107422116A CN201710294863.8A CN201710294863A CN107422116A CN 107422116 A CN107422116 A CN 107422116A CN 201710294863 A CN201710294863 A CN 201710294863A CN 107422116 A CN107422116 A CN 107422116A
- Authority
- CN
- China
- Prior art keywords
- hiv
- concentration
- antigen
- coated
- types
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
Abstract
The present invention relates to a kind of biological detection reagent and its application method, the more particularly to a kind of confirmation of the types of HIV 1/2 and the two-in-one reagent of primary dcreening operation based on percolation and preparation method thereof.Preparation method of the present invention, comprises the following steps：The type antigens of HIV 1 and the type antigens of HIV 2 are coated with nitrocellulose filter.
Description
Technical field
The present invention relates to a kind of biological detection reagent and its application method, more particularly to a kind of HIV-1/ based on percolation
The confirmation of 2 types and the two-in-one reagent of primary dcreening operation and preparation method thereof.
Background technology
Existing HIV confirmations method is mainly WB, RIBA and carries out inspection-free survey of enzyme twice etc. using the product of different company,
These technologies realize that HIV confirmation speed is slower, cumbersome to meet that detected person checks confirmed results immediately, and detect
Sample can only use serum or blood plasma；HIV confirmation methods WB, RIBA that the country is recommended etc. are only used for HIV confirmation, without
The examination detection to people at highest risk can be used for.
The present invention develops a kind of quick detection reagent on the basis of existing technology, can be completed within 30min to first
Sieve and confirmed for the positive samples of HIV, and suitable for detection whole blood, serum and plasma sample.
Reagent of the present invention is detected by repetition to sample or dilution, confirm result can distinguish patient's infection be HIV-1 types,
The infection of HIV-2 types or HIV-1 and HIV-2 mixed infections, existing detection reagent can only realize the confirmation to HIV-1, and carry
Show whether infected by HIV -2.
Reagent of the present invention has higher detection sensitivity than RIBA, WB etc., shortens " window phase " of HIV detections, carries
High HIV detects effect.
The content of the invention
The present invention provides a kind of HIV-1/2 types confirmation based on percolation and the preparation method of the two-in-one reagent of primary dcreening operation, institute
Preparation method is stated, is comprised the following steps：HIV-1 types antigen and HIV-2 type antigens are coated with nitrocellulose filter.
Wherein, the coated HIV-1 types antigen and HIV-2 types antigen are various concentrations, wherein can identify HIV-1 and
The antigen coat concentration of HIV-2 antibody tests point is anti-higher than specific recognition HIV-1 antibody and HIV-2 antibody tests point respectively
Primordial covering concentration.
Preferably, method of the invention is as follows：
Four points are coated with nitrocellulose membrane, it is dense to be diluted to coating with probe coating buffer respectively for coated antigen
Degree, each press 0.5ul and carry out point sample, 1. wherein Quality Control point is coated with anti-human igg, it is 0.1mg/ml~5mg/ that it, which is coated with concentration,
ml；Test point 3. mix coating HIV-1 type antigen gp41 and HIV-2 type antigen gp36, its be coated with concentration be 0.1mg/ml~
5mg/ml；2. test point is coated with HIV-1 type antigen gp41+gp120, it is 0.01mg/ml~1mg/ml that it, which is coated with concentration, its concentration
To be less than test point 3. middle gp41 concentration, to ensure its specific recognition HIV-1 antibody, reduce the generation of false positive；Detection
4. point is coated with HIV-2 type antigen gp36, it is 0.01mg/ml~1mg/ml that it, which is coated with concentration, 3. its concentration will be less than test point in
Gp36 concentration.To ensure its specific recognition HIV-1 antibody, to reduce the generation of false positive；
Wherein the antigen concentration of test point 3. is 2-8 times of test point 2. antigen concentration, and the antigen concentration of test point 3. is
2-5 times of test point 4. antigen concentration.
37 DEG C of conditions are positioned over after the completion of coating to dry.The display of testing result, can be three kinds of forms or its
The combining form of its different Points And lines is shown in accompanying drawing 1.
The present invention further provides a kind of confirmation of HIV-1/2 types and primary dcreening operation based on percolation prepared using the above method
Two-in-one reagent and its application method.
When the reagent is used as Confirmation reagent, application method is as follows：Being firstly added sample to be tested, (serum, blood plasma are direct
Sample-adding, whole blood are loaded after the percolating device filtering that this patent provides), it is added dropwise and is marked with after sample penetrates into nitrocellulose membrane
Anti-human igg, protein A or protein G colloidal gold probe are developed the color and carry out result interpretation；First step interpretation：Such as
1. 2. 3. fruit is only developed the color simultaneously, then can confirm that for HIV it is positive and positive for HIV-1 types；If only 1. 3. 4. developed the color simultaneously,
Then can confirm that for HIV it is positive and to prompt it be the HIV-2 types positive；1. if 2. 3. 4. developed the color, can confirm that as HIV sun
Property, and it is positive for HIV-1 types, and prompt be that HIV-1/2 is simultaneously positive.Other all situations are uncertain.Second step
Interpretation：For uncertain sentence read result, if situation about only 1. 2. developing the color, then do simultaneously and double sample size and by sample
Carry out two experiments of detection after one times of dilution, only 1. 2. 3. colour developing or only 1. 2. 4. colour developing or 1. occurs in the experiment of any of which one
2. 3. the situation that 4. develops the color, then return to the first step and carry out result interpretation.
When the reagent is used as preliminary screening agent, application method is as follows：Being firstly added sample to be tested, (serum, blood plasma are direct
Sample-adding, whole blood are loaded after the percolating device filtering that this patent provides), it is added dropwise and is marked with after sample penetrates into nitrocellulose membrane
Anti-human igg, protein A or protein G colloidal gold probe are developed the color and carry out result interpretation.If only 1. developing the color,
Sample is HIV negative；1. if 2. develop the color simultaneously, interpretation is HIV positive, and whether 3. 4. develop the color does not influence sentencing for final yin and yang attribute
Read, only on the basis of result interpretation is the positive, it may be that HIV-1 types are positive or HIV-2 types are positive or HIV-1/2 is same to prompt it
When it is positive.
The present invention be based on dot immuno gold filtration assay principle, by set hemofiltration device, immunity percolation detection means, solidify
The composition detection architectures such as gold mark secondary antibody, sample diluting liquid, cleaning solution.
Therefore, the present invention further provides detection architecture, including plastic mould, absorbent material, nitrocellulose filter (NC
Film) composition immunity percolation device, on NC films be coated with anti-human igg Quality Control point (line) and HIV three kinds of antigens point (line),
One of which is that HIV 1+2 mix coated antigen, and another two groups are respectively the specific antigens of HIV-1 and HIV-2.
By the detection architecture of the present invention, the detection three times of HIV confirmations can be met, ensure its specific recognition HIV-1
Antibody, to reduce the generation of false positive.
The present invention further comprises the processing of sample to be tested：Its method is, for sample to be detected, if whole blood
This, need to press 1 by blood Sample dilution:After 1 dilution, add in hemofiltration device, 1 drop (about 40ul) liquid of filtering is direct
It is added dropwise on NC films；Then directly take 1 drop (about 40ul) to be added dropwise on NC films if serum, plasma sample, used after liquid percolates are complete
The collaurum of anti-human igg is developed the color.
As a result interpretation：When the sample that this reagent is used for the HIV primary dcreening operations positive carries out confirmation detection, if only showing 1. point,
Sample is detected as feminine gender；Display simultaneously 1. 2. 3. 3 points then judge that tester is positive for HIV-1；Display 1. 2. 4. 3 when then
It is determined as that HIV-2 infects；When 1. 2. 3. 4. developing the color, it is determined as that HIV-1 infects, prompts possible infected by HIV -2 simultaneously；If inspection
Survey result for be 1. 3. then it is uncertain, will by be loaded twice with dilution 2 times detect respectively, further determine that whether sample is sun
Property, if it is double detection be respectively 1. 3. point colour developing and 1. 2. 3. 3 points colour developing if be determined as the positive, be otherwise judged to waiting to confirm；Other
Colour developing result is invalid detection.Detected sample is finally provided as negative, positive or probabilistic result.In emergency circumstances originally
When product is used for the detection of HIV primary dcreening operations, as long as meeting that 1. 2. sample is determined as the HIV antibody positive by test point colour developing, and select
Other reagents carry out confirmation detection to sample, determine whether sample is the HIV positives；, can be direct when only 1. Quality Control point develops the color
The sample is determined as HIV feminine genders.
The present invention highly shortened the HIV confirmation time, by will sample be confirmed, repeating detection using dilution can be with
Infected by HIV -1 or HIV-2 infection are distinguished, so as to reach while the purpose of parting.
HIV confirmations can be carried out using whole blood sample, without preparing serum or blood plasma；
This reagent has higher detection sensitivity, shortens " window phase " of HIV detections, improves HIV detection effects.
It is technical solution of the present invention and prior art implementation result comparison sheet below：
Brief description of the drawings
Fig. 1 coating forms include but is not limited to Fig. 1 several forms：
Fig. 2 is to serum, blood plasma pattern this progress HIV antibody detection, antigen distribution map on NC films
Fig. 3 is to serum, blood plasma pattern this progress HIV antibody detection, interpretation as a result
Fig. 4 is to serum, blood plasma pattern this progress HIV antibody detection, testing result citing
Fig. 5 is to whole blood pattern this progress HIV antibody detection, antigen distribution map on NC films
Fig. 6 is to whole blood pattern this progress HIV antibody detection, interpretation as a result
Fig. 7 is to whole blood pattern this progress HIV antibody detection, testing result citing
Embodiment
The present invention is further illustrated by the following examples, but not as limitation of the present invention.
Embodiment 1
Using the present invention to serum, blood plasma pattern this progress HIV antibody detection：
One, matched reagents：
Probe coating buffer：Add 20 μ L isopropanols in 980 μ L 1XPBS solution, concussion mixes, packing be stored in 4 DEG C it is standby
With.
Cleaning solution PBST：50 μ L tweens are dissolved in 10ml 1XPBS solution in -20, and concussion mixes, room temperature preservation.
Colloidal gold labeled monoclonal antibody dilution：Weigh 100mg BSA to be dissolved in 10ml 1XPBS solution, concussion mixes.
Collaurum cured sheets：The collaurum of liquid is soaked into multi-layer filter paper, carries out freezing solidification, and is cut into small pieces, after
Continue for developing the color.
Two, implementing procedures
NC films pre-process
NC films are cut into 1.25cmX20cm strip, 37 DEG C is put in deionized water and soaks 1 hour, ambient temperature overnight is dried in the air
It is dry standby, pay attention to adding drier when soaked NC films are placed to lunch box, NC films is fully kept drying.
The assembling of immunity percolation device for fast detecting
It is about 2-3mm that blotting paper first is folded into thickness, and size about 2.5cmX2.5cm grids are placed in the modeling of immunity percolation device
Expect in mould (4cmX2.7cmX0.5cm), used in the square piece for the 1.25cmX1.25cm sizes that the NC films by pretreatment are cut into
Tweezers gripping is put into blotting paper center, and covering Intermediate Gray has the die cover (diameter 8mm) of loading wells, and NC films is fixed on sample-adding
Kong Zhong, device are placed in standby at dried and clean after being completed.
Three, actual productions and pattern detection flow
Carry out point sample to NC films, four kinds of antigen concentrations are the 1. 0.38mg/ml anti-anti-human igg of Quality Control point mouse, 2. gp41
0.065mg/ml, 3. gp36+gp41 0.25mg/ml, 4. gp360.09mg/ml, every kind of antigen press 0.5 μ L point samples, antigen is in NC
Distribution such as Fig. 2 on film：The immunity percolation device for fast detecting put is put in after drying incubation 4-5 hours in 37 DEG C of insulating boxs and taken
Go out, directly carry out test experience or be positioned over 4 DEG C to save backup.
It is before detection that device and the anti-human collaurum secondary antibody of agents useful for same is molten if being positioned over 4 DEG C of detection reagents saved backup
Liquid, PBST move to room temperature from 4 DEG C of refrigerator and are balanced, and could be used to detect.
Before detection, 3 drop (about 100 μ L) washing lotion PBST wetting NC films are added in well, wait PBST diafiltrations.
After PBST was percolated NC films completely, melts completely after the fresh preparations of a drop about 40ul or -20 DEG C are preserved and recover
Serum/plasma to room temperature is added dropwise on NC films, waits diafiltration.
After its serum/plasma sample fully penetrates into, add 6 drop (about 200 μ L) washing lotions and rinse NC films.
With colloidal gold labeled monoclonal antibody diluted gold mark secondary antibody to working concentration, 40 μ L are taken to be added drop-wise on NC films.
After gold mark secondary antibody fully penetrates into, 6 drop (about 200 μ L) PBST wash liquid NC films are added.
As a result interpretation, is as a result shown in Fig. 3：
Fig. 4 is shown in testing result citing：
Embodiment 2：
Using the present invention to whole blood pattern this progress HIV antibody detection
Matched reagent：
Disinfecting cotton swab, blood taking needle, sterile small suction pipe.
Probe coating buffer：Add 20 μ L isopropanols in 980 μ L 1XPBS solution, concussion mixes, packing be stored in 4 DEG C it is standby
With.
Cleaning solution PBST：50 μ L tweens are dissolved in 10ml 1XPBS solution in -20, and concussion mixes, room temperature preservation.
Full cell pyrolysis liquid：The whole blood cells lysate of the special inhibitor containing protein coacervation of our company.Colloid gold label
Antibody diluent：Weigh 100mg BSA to be dissolved in 10ml 1XPBS solution, concussion mixes.
Collaurum cured sheets：The collaurum of liquid is soaked into multi-layer filter paper, carries out freezing solidification, and is cut into small pieces, after
Continue for developing the color.
Implementing procedure
NC films pre-process
NC films are cut into 1.25cmX20cm strip, 37 DEG C is put in deionized water and soaks 1 hour, ambient temperature overnight is dried in the air
It is dry standby, pay attention to adding drier when soaked NC films are placed to lunch box, NC films is fully kept drying.
The assembling of immunity percolation device for fast detecting
It is about 2-3mm that blotting paper first is folded into thickness, and about 2.5cmX2.5cm grids are placed in immunity percolation device plastics
In mould (4cmX2.7cmX0.5cm), in the square piece tweezer for the 1.25cmX1.25cm sizes that the NC films by pretreatment are cut into
Sub-folder is picked and placeed into blotting paper center, and covering Intermediate Gray has the die cover (diameter 8mm) of loading wells, and NC films is fixed on well
In, device is placed in standby at dried and clean after being completed.
Three, reagents produce and pattern detection flow
Carry out point sample to NC films, four kinds of antigen concentrations are the 1. 0.38mg/ml anti-anti-human igg of Quality Control point mouse, 2. gp41
0.065mg/ml, 3. gp36+gp41 0.25mg/ml, 4. gp360.09mg/ml, every kind of antigen press 0.5 μ L point samples, antigen is in NC
Fig. 5 is shown in distribution on film：The immunity percolation device for fast detecting put is put in after drying incubation 4-5 hours in 37 DEG C of insulating boxs and taken
Go out, directly carry out test experience or be positioned over 4 DEG C to save backup.
Sample collection：After being carried out disinfection using aseptic cotton, fetching point blood is pricked with blood taking needle, it is fresh to draw 3 drops with small suction pipe
For blood into the centrifuge tube added with 3 drop cell pyrolysis liquids, rapid be well mixed makes cell fully crack.
It is before detection that device and the anti-human collaurum secondary antibody of agents useful for same is molten if being positioned over 4 DEG C of detection reagents saved backup
Liquid, PBST move to room temperature from 4 DEG C of refrigerator and are balanced, and could be used to detect.
Before detection, 3 drop (about 100 μ L) washing lotion PBST wetting NC films are added in well, wait PBST diafiltrations.
After PBST was percolated NC films completely, the 3 full cell pyrolysis liquids of drop are added.
After its sample fully penetrates into, add 6 drop (about 200 μ L) washing lotions and rinse NC films.
With colloidal gold labeled monoclonal antibody diluted gold mark secondary antibody to working concentration, 40 μ L are taken to be added drop-wise on NC films.
After gold mark secondary antibody fully penetrates into, 6 drop (about 200 μ L) PBST wash liquid NC films are added.
As a result interpretation, as a result explain and see Fig. 6.
Fig. 7 is shown in testing result citing.
Claims (8)
1. a kind of HIV-1/2 types based on percolation confirm the preparation method with the two-in-one reagent of primary dcreening operation, it is characterised in that including
Following steps：HIV-1 types antigen and HIV-2 type antigens are coated with nitrocellulose filter.
2. according to the method for claim 1, it is characterised in that coated HIV-1 types antigen and HIV-2 types resist on test point
Originally it was various concentrations, wherein can identify the antigen coat concentration of HIV-1 and HIV-2 antibody tests point higher than special respectively simultaneously
Property identification HIV-1 antibody and HIV-2 antibody tests point antigen coat concentration.
3. according to the method for claim 1, it is characterised in that four points are coated with nitrocellulose filter, for being coated with
Antigen be diluted to coating concentration with probe coating buffer respectively, each press 0.5ul and carry out point sample, 1. wherein Quality Control point is coated with anti-
Human IgG, it is 0.1mg/ml~5mg/ml that it, which is coated with concentration,；3. test point mixes coating HIV-1 type antigen gp41 and HIV-2 types and resisted
Former gp36, it is 0.1mg/ml~5mg/ml that it, which is coated with concentration,；2. test point is coated with HIV-1 type antigen gp41+gp120, it is wrapped
It is 0.01mg/ml~1mg/ml by concentration, its concentration will be less than test point 3. middle gp41 concentration, 4. test point is coated with HIV-2
Type antigen gp36, it be 0.01mg/ml~1mg/ml that it, which is coated with concentration, and its concentration will be less than test point 3. middle gp36 concentration.
4. according to the method for claim 3, it is characterised in that wherein the antigen concentration of test point 3. is test point 2. antigen
2-8 times of concentration, the antigen concentration of test point 3. are 2-5 times of test point 4. antigen concentration.
5. a kind of HIV-1/2 types based on percolation confirm and the two-in-one reagent of primary dcreening operation, it is characterised in that the reagent is according to power
Profit requires prepared by 3 method.
6. the application method of reagent described in claim 5, it is characterised in that when the reagent is used as Confirmation reagent, method is such as
Under：Being firstly added sample to be tested, (serum, blood plasma are directly loaded, and whole blood adds after the percolating device filtering that this patent provides
Sample), it is added dropwise after sample penetrates into nitrocellulose membrane and is marked with anti-human igg, protein A or protein G colloidal gold probe
Developed the color and carry out result interpretation；First step interpretation：If only 1. 2. 3. developed the color simultaneously, can confirm that for HIV it is positive, and
It is positive for HIV-1 types；If only 1. 3. 4. developed the color simultaneously, can confirm that for HIV it is positive and to prompt it may be HIV-2 types sun
Property；It 1. if 2. 3. 4. developed the color, can confirm that positive and positive for HIV-1 types for HIV, and it may be HIV-1/2 to prompt
It is simultaneously positive.Other all situations are uncertain.Second step interpretation：For uncertain sentence read result, if only 1. 2.
The situation of colour developing, then do simultaneously and sample size is doubled and will carried out after one times of Sample Dilution two experiments of detection, any of which one
Individual experiment occurs only 1. 2. 3. developing the color or only 1. 2. 4. developing the color or the situation that 1. 2. 3. 4. develops the color, then returns to the first step and carry out result
Interpretation.
7. the application method of reagent described in claim 5, it is characterised in that when the reagent is used as preliminary screening agent, method is such as
Under：Being firstly added sample to be tested, (serum, blood plasma are directly loaded, and whole blood adds after the percolating device filtering that this patent provides
Sample), it is added dropwise after sample penetrates into nitrocellulose membrane and is marked with anti-human igg, protein A or protein G colloidal gold probe
Developed the color and carry out result interpretation.If only 1. developing the color, sample is HIV negative；1. if 2. develop the color simultaneously, interpretation HIV
Whether the positive, 3. 4. developing the color does not influence the interpretation of final yin and yang attribute, only on the basis of result interpretation is the positive, prompts it may
For the HIV-1 types positive or HIV-2 types are positive or HIV-1/2 is simultaneously positive.
8. a kind of detection architecture, including two-in-one reagent prepared by method according to claim 3, the detection architecture also include
Plastic mould, absorbent material, the immunity percolation device of nitrocellulose filter (NC films) composition, are coated with anti-human igg on NC films
The point (line) of Quality Control point (line) and HIV three kinds of antigens, one of which are that HIV 1+2 mix coated antigen, another two groups of difference
For the specific antigens of HIV-1 and HIV-2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710294863.8A CN107422116B (en) | 2017-04-28 | 2017-04-28 | A kind of HIV-1/2 type confirmation based on percolation and the two-in-one reagent of primary dcreening operation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710294863.8A CN107422116B (en) | 2017-04-28 | 2017-04-28 | A kind of HIV-1/2 type confirmation based on percolation and the two-in-one reagent of primary dcreening operation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107422116A true CN107422116A (en) | 2017-12-01 |
| CN107422116B CN107422116B (en) | 2019-08-27 |
Family
ID=60424815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710294863.8A Active CN107422116B (en) | 2017-04-28 | 2017-04-28 | A kind of HIV-1/2 type confirmation based on percolation and the two-in-one reagent of primary dcreening operation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107422116B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1858594A (en) * | 2006-04-14 | 2006-11-08 | 武汉大学 | Multiple index quick detecting method for human immune defect virus antibody |
| DE202006018054U1 (en) * | 2006-03-18 | 2007-03-15 | Institut Virion/Serion Gmbh | Diagnostic test system for HIV antibodies in human samples, comprises HIV1 and HIV2 antigens as detector molecules bound to carrier particles marked with fluorescent dyes, in particle sets characterised by specific codings |
| CN102053153A (en) * | 2010-11-25 | 2011-05-11 | 西安微通生物技术有限公司 | Dot immuno gold directed infiltration detection kit and application thereof |
| CN103376318A (en) * | 2012-04-23 | 2013-10-30 | 齐明山 | HIV (human immunodeficiency virus) antibody recognition reagent |
-
2017
- 2017-04-28 CN CN201710294863.8A patent/CN107422116B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202006018054U1 (en) * | 2006-03-18 | 2007-03-15 | Institut Virion/Serion Gmbh | Diagnostic test system for HIV antibodies in human samples, comprises HIV1 and HIV2 antigens as detector molecules bound to carrier particles marked with fluorescent dyes, in particle sets characterised by specific codings |
| CN1858594A (en) * | 2006-04-14 | 2006-11-08 | 武汉大学 | Multiple index quick detecting method for human immune defect virus antibody |
| CN102053153A (en) * | 2010-11-25 | 2011-05-11 | 西安微通生物技术有限公司 | Dot immuno gold directed infiltration detection kit and application thereof |
| CN103376318A (en) * | 2012-04-23 | 2013-10-30 | 齐明山 | HIV (human immunodeficiency virus) antibody recognition reagent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107422116B (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105445449B (en) | Saliva uric acid rapid semi-quantitative detection means and preparation method thereof | |
| CN112326966A (en) | Novel rapid detection kit for coronavirus antigen, and preparation method and application thereof | |
| CN106093378A (en) | Detection dog echinococcus granulosus infection colloidal gold immune chromatography test and preparation method | |
| CN107918011A (en) | The detection method and detection kit of fungi | |
| CN101178404B (en) | Human immunodeficiency virus antibody chemiluminescence immune analyzing diagnose reagent box and method of producing the same | |
| CN101566631A (en) | Magnetic immunochromatographic test strip for combined detection of HIV-1+2 antibody and P24 antigen and preparation method thereof | |
| CN109459575A (en) | A kind of ABO&RhD blood group detection device | |
| WO2016111619A1 (en) | Methods for detecting a marker for active tuberculosis | |
| CN107966561A (en) | A kind of test strips and kit for detecting HIV antibody | |
| JP6712863B2 (en) | Method for detecting allergen by immunochromatography | |
| JPWO2017213227A1 (en) | Immunochromatographic test strip and sample addition device for extracting and measuring sugar chain antigen, and immunochromatography method using the same | |
| CN104569400B (en) | A kind of incomplete antibody examination colloidal gold kit and preparation method thereof | |
| CN101487843A (en) | Fast urine HIV detection diagnosis test paper and method for producing the same | |
| CN107422116B (en) | A kind of HIV-1/2 type confirmation based on percolation and the two-in-one reagent of primary dcreening operation and preparation method thereof | |
| US20080166701A1 (en) | Immunoassay Method and Immunoassay Kit to Be Used Therein | |
| CN109946458A (en) | A kind of fluorescent test paper of quick detection Porcine epidemic diarrhea virus and preparation and application | |
| CN109073643A (en) | The forming method and immunochromatography check device in the sample addition portion of immunochromatography check device | |
| CN109975541A (en) | A kind of detection card and preparation method thereof of quick detection canine distemper virus antigen | |
| CN107589252A (en) | A kind of H5 subtype avian influenza virus fluorescent microsphere detection card and its application | |
| CN107561281A (en) | A kind of centrichromatography colloid gold immune detection technique and application thereof | |
| CN101762693A (en) | Magnetic immunochromatographic strip for detection of TP antibody and preparation method thereof | |
| CN103149355B (en) | A kind of Test paper card that utilizes sandwich method to detect Brucella abortus antibody | |
| CN108051591A (en) | A kind of bird flu H9 subtype virus antibody rapid quantitative detection reagent box and its application | |
| CN107290547A (en) | A kind of infertile quick detection kit and preparation method thereof | |
| CN212989383U (en) | Coronavirus antibody joint inspection test paper strip and reagent card |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Zha Inventor after: He Ran Inventor before: Zhang Zha |
|
| CB03 | Change of inventor or designer information |